Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Open-label, Two-part Study to Evaluate the Mechanism of Action of Itepekimab (Anti-IL-33 mAb) on Airway Inflammation in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT05326412 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT05326412
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05326412 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Open-label, Two-part Study to Evaluate the Mechanism of Action of Itepekimab (Anti-IL-33 mAb) on Airway Inflammation in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Completed
Start date
May 19, 2022
Completion date
July 25, 2025
Enrollment
49 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

chronic obstructive pulmonary disease